Germany Joins Probe Of China Heparin Sources
This article was originally published in PharmAsia News
German authorities are joining in the search for answers to the contamination in China of active ingredients in the blood-thinner heparin. The drug produced by Rotexmedica has been linked to about 80 allergic reactions in German patients, leading to a national recall. German authorities identified Changzhou Quianhong Bio Pharma and Yantai Dongcheng Biochemicals as the sources of heparin API and asked heparin producers to check to see if their API came from China. Although the U.S. FDA said its investigation of the Baxter source found concentrations as high as 20 percent of a substance that may be counterfeit, it has not established whether the same substance was responsible for allergic reactions. (Click here for more
You may also be interested in...
Mexico's Genomma Lab recorded strong double-digit growth for its OTC business in the second quarter as sales more than doubled at its US consumer health operation.
New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.